Distinct cellular dynamics associated with response to CAR-T therapy for refractory B-cell lymphoma
Nicholas J. Haradhvala(Broad Institute), Marcela V. Maus(Center for Cancer Research)
Cited by 20
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing
|Nature Biotechnology|2019|724
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
|The Lancet|2020|358
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
|Computational and Structural Biotechnology Journal|2016|281
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
|Science Translational Medicine|2021|257